Almirall, S.A. (BME:ALM)
Spain · Delayed Price · Currency is EUR 12.50
-0.08 (-0.64%)
Apr 28, 2026, 1:33 PM CET
Almirall Revenue
In the year 2025, Almirall had annual revenue of 1.11B EUR with 12.51% growth. Almirall had revenue of 288.93M in the quarter ending December 31, 2025, with 11.37% growth.
Revenue
1.11B
Revenue Growth
+12.51%
P/S Ratio
2.42
Revenue / Employee
528.72K
Employees
2,108
Market Cap
2.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.11B | 123.91M | 12.51% |
| Dec 31, 2024 | 990.63M | 91.84M | 10.22% |
| Dec 31, 2023 | 898.79M | 20.28M | 2.31% |
| Dec 31, 2022 | 878.51M | 42.01M | 5.02% |
| Dec 31, 2021 | 836.50M | 22.01M | 2.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.52B |
| Laboratorios Farmaceuticos Rovi | 743.48M |
| Faes Farma | 626.99M |
| Laboratorio Reig Jofre | 336.68M |
| Clínica Baviera | 304.91M |
| Prim, S.A. | 251.89M |
| Pharma Mar | 221.39M |
| Atrys Health | 144.31M |
Almirall News
- 15 days ago - Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology - Business Wire
- 4 weeks ago - Almirall, S.A.: Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis - Finanz Nachrichten
- 4 weeks ago - Almirall S.A.: AAD 2026: Almirall Presents New Clinical and Real-world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne - Finanz Nachrichten
- 4 weeks ago - AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne - Business Wire
- 5 weeks ago - Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology - Business Wire
- 6 weeks ago - Spain's Almirall in talks with 'dozens' of firms to license China assets, CEO says - Reuters
- 6 weeks ago - Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships - Business Wire
- 2 months ago - Almirall profit quadruples in 2025 as dermatology fuels growth push - Invezz